SCHEMBL563260

SCHEMBL563260

CCCCCc1nc(NCc2ccc(OC)cc2)c(N)c(NCCCCS(C)(=O)=O)c1Cc1ccc(OC)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 6/20 0.42
TLR8 Q9NR97 1/20 0.39
PDE4A P27815 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37
PDE3B Q13370 1/20 0.37
PDE3A Q14432 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA9 Q16790 1/20 0.37
GHSR Q92847 5/20 0.37
PTGS2 P35354 1/20 0.35
APP P05067 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPK1 P28482 1/20 0.35
SLC2A1 P11166 1/20 0.35
TP53 P04637 1/20 0.35
MAPT P10636 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL562853 0.88 EGFR (0.46) TLR7TLR8PDE4APDE4BPDE4C
SCHEMBL562962 0.85 TLR7 (0.43) TLR7TLR8PDE4APDE4BPDE4C
SCHEMBL563155 0.82 PDE4A (0.45) TLR7TLR8PDE4APDE4BPDE4C
SCHEMBL563165 0.81 PGK1 (0.41) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL563829 0.80 ALDH1A1 (0.44) TLR7TLR8CA1CA2CA9
SCHEMBL562174 0.78 APP (0.42) TLR7TLR8PDE4APDE4BPDE4C
SCHEMBL563141 0.78 PRKCQ (0.38) TLR7TLR8PDE4APDE4BPDE4C
SCHEMBL563543 0.76 MAPT (0.48) TLR7PDE4APDE4BPDE4CPDE4D
SCHEMBL563105 0.73 EGFR (0.54) TLR7CA1CA2ALDH1A1MAPK1
SCHEMBL562499 0.71 MAPT (0.40) PTGS2ALDH1A1MAPK1SLC2A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120035209-A1 Hydroxy Substituted 1H-Imidazopyridines and Methods PFIZER INC. (US) 2012-02-09 US disclosed
US-20100152230-A1 HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS PFIZER INC. 2010-06-17 US disclosed
EP-1924581-A1 HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS Pfizer, Inc. (US) 2008-05-28 EP disclosed
WO-2007028129-A1 HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS PFIZER INC. (US) 2007-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152230-A1 HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS IL4, IL2, IL4I1 TLR7 210/4885TLR8 254/4885PDE4A 687/4885
US-20120035209-A1 Hydroxy Substituted 1H-Imidazopyridines and Methods IL2, IL4, IL4I1 TLR7 231/4885TLR8 274/4885PDE4A 782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.